Tech Company Financing Transactions
Seres Therapeutics Funding Round
Seres Therapeutics, operating out of Cambridge, secured $3.6 million in funding from Carb-X.
Transaction Overview
Company Name
Announced On
10/29/2025
Transaction Type
Debt
Amount
$3,600,000
Round
Undisclosed
Investors
Proceeds Purpose
The grant will support development and manufacturing of an oral liquid formulation of Seres' Breakthrough Therapy designated SER-155, for medically vulnerable patient populations at risk of bloodstream infections (BSIs), including antimicrobial resistant infections, who cannot be dosed with oral capsules, such as intubated patients in the ICU.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Sidney St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Seres Therapeutics (NASDAQ: MCRB) is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roger Pomerantz
Chief Financial Officer
Eric Shaff
Chief Medical Officer
Michele Trucksis
Chief Scientific Officer
David Cook
Chief Technical Officer
John Aunins
VP - Bus. Development
Henry Rath
VP - General Counsel
Thomas DesRosier
VP - Operations
Carol Cullinan
VP - R & D
Matthew Henn
VP - Regulatory Affairs
Barbara McGovern
Browse more venture capital transactions:
Prev: 10/29/2025: Rarity PBC venture capital transaction
Next: 10/29/2025: VentureMed Group venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs